Ongoing investigations of targeted therapeutic agents and their increased clinical
applications, together with research in genomics and proteomics, have explored a variety of …

Background Radiology is the current standard for monitoring treatment responses in lung
cancer. Limited sensitivity, exposure to ionizing radiations and related sequelae constitute …

e22086 Background: Cancer is a disease caused by the accumulation of genetic alterations
which initiate and promote the uncontrolled growth and metastasis of cancer cells. These …

Circulating tumor DNA (ctDNA) shed from cancer cells into the peripheral blood can be non-
invasively collected and tested for the presence of tumor-specific mutations. Mutations …

In this paper we report long-term therapy management based on iterative de novo molecular
and cellular analysis in a case of metastatic non-small cell lung cancer (NSCLC), with prior …

Genetic sequencing of malignancies has become increasingly important to uncover
therapeutic targets and capture the tumor's dynamic changes to drug sensitivity and …

Background The gold standard for clinical monitoring of lung cancer is CT imagining which
is subjective and insensitive requiring a minimal of 2-3 months between repeat scans to be …

Liquid biopsy followed by analy sis of circulating tumour DNA (ctDNA) for targetable driver
alterations is beginning to enter the routine clinical management of patients with …

Upfront tumour genotyping is now considered an essential step in guiding treatment
decision-making in the management of patients with advanced-stage non-small-cell lung …

Circulating tumor DNA (ctDNA) testing is widely used in oncology to identify genomic
alterations. Our featured experts review the strengths and limitations of ctDNA testing in non …